Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Peripheral lymph nodes contain migratory and resident innate lymphoid cell populations.

Dutton EE, Gajdasik DW, Willis C, Fiancette R, Bishop EL, Camelo A, Sleeman MA, Coccia M, Didierlaurent AM, Tomura M, Pilataxi F, Morehouse CA, Carlesso G, Withers DR.

Sci Immunol. 2019 May 31;4(35). pii: eaau8082. doi: 10.1126/sciimmunol.aau8082.

PMID:
31152090
2.

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

Burny W, Marchant A, Hervé C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J; ECR-008 study group.

Vaccine. 2019 Mar 28;37(14):2004-2015. doi: 10.1016/j.vaccine.2019.02.015. Epub 2019 Mar 5.

3.

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.

Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, Normand-Bayle M, Oostvogels L, Da Silva FT, Vassilev V, Vinals C, Brecx A.

Expert Rev Vaccines. 2018 Jul;17(7):619-634. doi: 10.1080/14760584.2018.1495565. Epub 2018 Jul 20. Review.

PMID:
30028651
4.

Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties.

Givord C, Welsby I, Detienne S, Thomas S, Assabban A, Lima Silva V, Molle C, Gineste R, Vermeersch M, Perez-Morga D, Leo O, Collignon C, Didierlaurent AM, Goriely S.

NPJ Vaccines. 2018 Jun 28;3:20. doi: 10.1038/s41541-018-0058-4. eCollection 2018.

5.

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.

Del Giudice G, Rappuoli R, Didierlaurent AM.

Semin Immunol. 2018 Oct;39:14-21. doi: 10.1016/j.smim.2018.05.001. Epub 2018 May 23. Review.

6.

Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Van Deun K, Smilde AK, van den Berg RA, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, van der Most R, Didierlaurent AM.

NPJ Vaccines. 2018 Mar 21;3:13. doi: 10.1038/s41541-018-0047-7. eCollection 2018.

7.

Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM.

NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017. Erratum in: NPJ Vaccines. 2018 Mar 21;3:13.

8.

The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.

Neeland MR, Shi W, Collignon C, Meeusen ENT, Didierlaurent AM, de Veer MJ.

Clin Exp Immunol. 2018 Apr;192(1):46-53. doi: 10.1111/cei.13088. Epub 2018 Jan 23.

9.

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.

Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, Janssens M, Leroux-Roels G, Marchant A, van den Berg RA, Garçon N, van der Most R, Didierlaurent AM; ECR-002 Study Group.

Front Immunol. 2017 Aug 14;8:943. doi: 10.3389/fimmu.2017.00943. eCollection 2017.

10.

Towards an evidence based approach for the development of adjuvanted vaccines.

O'Hagan DT, Friedland LR, Hanon E, Didierlaurent AM.

Curr Opin Immunol. 2017 Aug;47:93-102. doi: 10.1016/j.coi.2017.07.010. Epub 2017 Jul 26. Review.

11.

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E, Didierlaurent AM, van der Most RG.

Front Immunol. 2017 May 23;8:557. doi: 10.3389/fimmu.2017.00557. eCollection 2017.

12.

Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21.

Welsby I, Detienne S, N'Kuli F, Thomas S, Wouters S, Bechtold V, De Wit D, Gineste R, Reinheckel T, Elouahabi A, Courtoy PJ, Didierlaurent AM, Goriely S.

Front Immunol. 2017 Jan 5;7:663. doi: 10.3389/fimmu.2016.00663. eCollection 2016.

13.

Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01.

Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, Van Maele L, Thomas S, Swertvaegher M, Detavernier A, Elouahabi A, Goriely S, Didierlaurent AM.

Sci Rep. 2016 Dec 20;6:39475. doi: 10.1038/srep39475.

14.

The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.

Neeland MR, Shi W, Collignon C, Taubenheim N, Meeusen EN, Didierlaurent AM, de Veer MJ.

J Immunol. 2016 Oct 1;197(7):2704-14. doi: 10.4049/jimmunol.1600817. Epub 2016 Aug 22.

15.

Adjuvant system AS01: helping to overcome the challenges of modern vaccines.

Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N.

Expert Rev Vaccines. 2017 Jan;16(1):55-63. Epub 2016 Aug 2. Review.

PMID:
27448771
16.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M.

Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25.

17.

Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.

Hallé M, Tribout-Jover P, Lanteigne AM, Boulais J, St-Jean JR, Jodoin R, Girouard MP, Constantin F, Migneault A, Renaud F, Didierlaurent AM, Mallett CP, Burkhart D, Pilorget A, Palmantier R, Larocque D.

J Immunol Methods. 2015 Sep;424:64-79. doi: 10.1016/j.jim.2015.05.002. Epub 2015 May 19.

18.

Pectate lyase pollen allergens: sensitization profiles and cross-reactivity pattern.

Pichler U, Hauser M, Wolf M, Bernardi ML, Gadermaier G, Weiss R, Ebner C, Yokoi H, Takai T, Didierlaurent A, Rafaiani C, Briza P, Mari A, Behrendt H, Wallner M, Ferreira F.

PLoS One. 2015 May 15;10(5):e0120038. doi: 10.1371/journal.pone.0120038. eCollection 2015.

19.

Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines.

Segal L, Wouters S, Morelle D, Gautier G, Le Gal J, Martin T, Kuper F, Destexhe E, Didierlaurent AM, Garçon N.

J Appl Toxicol. 2015 Dec;35(12):1564-76. doi: 10.1002/jat.3130. Epub 2015 Feb 27.

PMID:
25727696
20.

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garçon N, Van Mechelen M, Morel S.

J Immunol. 2014 Aug 15;193(4):1920-30. doi: 10.4049/jimmunol.1400948. Epub 2014 Jul 14.

21.

Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Leroux-Roels G, Bourguignon P, Willekens J, Janssens M, Clement F, Didierlaurent AM, Fissette L, Roman F, Boutriau D.

Clin Vaccine Immunol. 2014 Mar;21(3):302-11. doi: 10.1128/CVI.00617-13. Epub 2014 Jan 3.

22.

Airway structural cells regulate TLR5-mediated mucosal adjuvant activity.

Van Maele L, Fougeron D, Janot L, Didierlaurent A, Cayet D, Tabareau J, Rumbo M, Corvo-Chamaillard S, Boulenouar S, Jeffs S, Vande Walle L, Lamkanfi M, Lemoine Y, Erard F, Hot D, Hussell T, Ryffel B, Benecke AG, Sirard JC.

Mucosal Immunol. 2014 May;7(3):489-500. doi: 10.1038/mi.2013.66. Epub 2013 Sep 25.

PMID:
24064672
23.

Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor.

Do Y, Didierlaurent AM, Ryu S, Koh H, Park CG, Park S, Perlin DS, Powell BS, Steinman RM.

Vaccine. 2012 Oct 5;30(45):6359-67. doi: 10.1016/j.vaccine.2012.08.051. Epub 2012 Sep 1.

24.

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM.

Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Review.

PMID:
22380826
25.

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.

Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M.

BioDrugs. 2011 Aug 1;25(4):217-26. doi: 10.2165/11591760-000000000-00000. Review.

PMID:
21815697
26.

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M.

Vaccine. 2011 Mar 16;29(13):2461-73. doi: 10.1016/j.vaccine.2011.01.011. Epub 2011 Jan 20.

PMID:
21256188
27.

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N.

J Immunol. 2009 Nov 15;183(10):6186-97. doi: 10.4049/jimmunol.0901474. Epub 2009 Oct 28.

28.

Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin.

Janot L, Sirard JC, Secher T, Noulin N, Fick L, Akira S, Uematsu S, Didierlaurent A, Hussell T, Ryffel B, Erard F.

Eur J Immunol. 2009 Jun;39(6):1587-96. doi: 10.1002/eji.200838907.

29.

High throughput screening of mixed-mode sorbents and optimisation using pre-packed lab-scale columns for the purification of the recombinant allergen rBet v 1a.

Brenac Brochier V, Chabre H, Lautrette A, Ravault V, Couret MN, Didierlaurent A, Moingeon P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2420-7. doi: 10.1016/j.jchromb.2009.03.020. Epub 2009 Mar 18.

PMID:
19345650
30.

Toll-like receptor 5- and lymphotoxin beta receptor-dependent epithelial Ccl20 expression involves the same NF-kappaB binding site but distinct NF-kappaB pathways and dynamics.

Sirard JC, Didierlaurent A, Cayet D, Sierro F, Rumbo M.

Biochim Biophys Acta. 2009 May;1789(5):386-94. doi: 10.1016/j.bbagrm.2009.03.001. Epub 2009 Mar 20.

31.

Production of native and modified recombinant Der p 1 molecules in tobacco plants.

Burtin D, Chabre H, Olagnier B, Didierlaurent A, Couret MN, Comeau D, Wambre E, Laparra H, Van Overtvelt L, Montandon F, Batard T, Jonval V, Lorphelin A, Merle C, Berrouet C, Parry L, Gomord V, Van Ree R, Moingeon P.

Clin Exp Allergy. 2009 May;39(5):760-70. doi: 10.1111/j.1365-2222.2009.03201.x. Epub 2009 Feb 18.

PMID:
19226276
32.

Manipulation of acute inflammatory lung disease.

Wissinger EL, Saldana J, Didierlaurent A, Hussell T.

Mucosal Immunol. 2008 Jul;1(4):265-78. doi: 10.1038/mi.2008.16. Epub 2008 May 7. Review.

PMID:
19079188
33.

Array-based profiling of ragweed and mugwort pollen allergens.

Gadermaier G, Wopfner N, Wallner M, Egger M, Didierlaurent A, Regl G, Aberger F, Lang R, Ferreira F, Hawranek T.

Allergy. 2008 Nov;63(11):1543-9. doi: 10.1111/j.1398-9995.2008.01780.x.

PMID:
18925891
34.

A critical function for CD200 in lung immune homeostasis and the severity of influenza infection.

Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T.

Nat Immunol. 2008 Sep;9(9):1074-83. doi: 10.1038/ni.1637. Epub 2008 Jul 27.

PMID:
18660812
35.

An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation.

Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, Broide D, Karin M, Lawrence T.

J Exp Med. 2008 Jun 9;205(6):1269-76. doi: 10.1084/jem.20080124. Epub 2008 May 19.

36.

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.

Corbett M, Bogers WM, Heeney JL, Gerber S, Genin C, Didierlaurent A, Oostermeijer H, Dubbes R, Braskamp G, Lerondel S, Gomez CE, Esteban M, Wagner R, Kondova I, Mooij P, Balla-Jhagjhoorsingh S, Beenhakker N, Koopman G, van der Burg S, Kraehenbuhl JP, Le Pape A.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2046-51. doi: 10.1073/pnas.0705191105. Epub 2008 Feb 11.

37.

The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification.

van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, Villalba M, Durham SR, Becker WM, Aalbers M, André C, Barber D, Cistero Bahima A, Custovic A, Didierlaurent A, Dolman C, Dorpema JW, Di Felice G, Eberhardt F, Fernandez Caldas E, Fernandez Rivas M, Fiebig H, Focke M, Fötisch K, Gadermaier G, Das RG, Gonzalez Mancebo E, Himly M, Kinaciyan T, Knulst AC, Kroon AM, Lepp U, Marco FM, Mari A, Moingeon P, Monsalve R, Neubauer A, Notten S, Ooievaar-de Heer P, Pauli G, Pini C, Purohit A, Quiralte J, Rak S, Raulf-Heimsoth M, San Miguel Moncin MM, Simpson B, Tsay A, Vailes L, Wallner M, Weber B.

Allergy. 2008 Mar;63(3):310-26. doi: 10.1111/j.1398-9995.2007.01612.x. Review.

PMID:
18269676
38.

Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection.

Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, Lawrence T, van Rijt LS, Lambrecht BN, Sirard JC, Hussell T.

J Exp Med. 2008 Feb 18;205(2):323-9. doi: 10.1084/jem.20070891. Epub 2008 Jan 28.

39.

Respiratory infections: do we ever recover?

Goulding J, Snelgrove R, Saldana J, Didierlaurent A, Cavanagh M, Gwyer E, Wales J, Wissinger EL, Hussell T.

Proc Am Thorac Soc. 2007 Dec;4(8):618-25. Review.

40.

The impact of successive infections on the lung microenvironment.

Didierlaurent A, Goulding J, Hussell T.

Immunology. 2007 Dec;122(4):457-65. Review.

41.

Validation of quantitative, allergen-specific ELISAs.

Becker WM, van Ree R, Fiebig H, Cromwell O, Weber B, Monsalve R, Barber D, Raulf-Heimsoth M, Moingeon P, Didierlaurent A, di Felice G, Pini C, Fötisch K, Vieths S.

Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):91-7; discussion 97, 100-4. No abstract available.

PMID:
17393728
42.

Sublingual vaccines based on wild-type recombinant allergens.

Van Overtvelt L, Razafindratsita A, St-Lu N, Didierlaurent A, Batard T, Lombardi V, Martin E, Moingeon P.

Eur Ann Allergy Clin Immunol. 2006 Sep;38(7):247-9.

PMID:
17124785
43.

Cross-reactivity between cypress pollen and peach: a report of seven cases.

Hugues B, Didierlaurent A, Charpin D.

Allergy. 2006 Oct;61(10):1241-3. No abstract available.

PMID:
16942582
44.

Pathogen-specific TLR signaling in mucosa: mutual contribution of microbial TLR agonists and virulence factors.

Sirard JC, Bayardo M, Didierlaurent A.

Eur J Immunol. 2006 Feb;36(2):260-3. Review.

45.

Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide.

Didierlaurent A, Brissoni B, Velin D, Aebi N, Tardivel A, Käslin E, Sirard JC, Angelov G, Tschopp J, Burns K.

Mol Cell Biol. 2006 Feb;26(3):735-42.

46.

Innate and acquired plasticity of the intestinal immune system.

Didierlaurent A, Simonet M, Sirard JC.

Cell Mol Life Sci. 2005 Jun;62(12):1285-7. Review. No abstract available.

47.

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.

Batard T, Didierlaurent A, Chabre H, Mothes N, Bussières L, Bohle B, Couret MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P, Krauth MT, André C, Valenta R, Moingeon P.

Int Arch Allergy Immunol. 2005 Mar;136(3):239-49. Epub 2005 Feb 16.

PMID:
15722633
48.

How the gut links innate and adaptive immunity.

Rumbo M, Anderle P, Didierlaurent A, Sierro F, Debard N, Sirard JC, Finke D, Kraehenbuhl JP.

Ann N Y Acad Sci. 2004 Dec;1029:16-21. Review.

PMID:
15681739
49.

The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study.

Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wüthrich B, Borelli S Jr, Giusti F, Seidenari S, Drzimalla K, Simon D, Disch R, Borelli S, Devillers AC, Oranje AP, De Raeve L, Hachem JP, Dangoisse C, Blondeel A, Song M, Breuer K, Wulf A, Werfel T, Roul S, Taieb A, Bolhaar S, Bruijnzeel-Koomen C, Brönnimann M, Braathen LR, Didierlaurent A, André C, Ring J.

Allergy. 2004 Dec;59(12):1318-25.

PMID:
15507101
50.

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.

Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, Orbea HA, Pantaleo G, Wagner R, Esteban M, Kraehenbuhl JP, Sirard JC.

Vaccine. 2004 Sep 3;22(25-26):3395-403.

PMID:
15308364

Supplemental Content

Loading ...
Support Center